EyePoint Pharmaceuticals

Investor FAQs

show all
Where is EyePoint Pharmaceuticals' corporate headquarters?

Watertown, Massachusetts

Where is the company incorporated?

Delaware

When did EyePoint Pharmaceuticals incorporate in the United States?

Founded in Australia, pSivida was incorporated in the U.S. in June 2008

What is EyePoint Pharmaceuticals' fiscal year end?

June 30th

Where is EyePoint Pharmaceuticals' stock traded?

EyePoint Pharmaceuticals stock is traded on the NASDAQ (PSDV), Australian (PVA), and Frankfurt (PV3) exchanges

How many license or collaboration agreements does EyePoint Pharmaceuticals' have?

We have license agreements with Bausch and Lomb for both the Vitrasert product and the Retisert product. We also have a license agreement with Alimera for ocular applications of the ILUVIEN device. We have a collaboration agreement with Pfizer for the Durasert device delivering latanoprost.

How many FDA and EV approved products have you developed?

We have 2 FDA approved products, Vitrasert and Retisert. Both are being sold by Bausch and Lomb. ILUVIEN received a positive outcome from the EU Decentralized Procedure and has subsequently received formal marketing authorization in the U.K., Austria, France, Germany, Portugal, Spain,Italy, Norway and Denmark.

Who is EyePoint Pharmaceuticals' transfer agent?

Computershare Investor Services

Whom do I contact with questions about my stock?

In the United States contact:

Argot Partners
Kimberly Minarovich
(646) 368-8014
kimberly@argotpartners.com

Joseph Rayne
(617) 340-6075
joseph@argotpartners.com

How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?

Contact:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940
United States of America
Phone: 781-575-2879
Fax: 781-575-3605

Does EyePoint Pharmaceuticals' have a direct stock purchase plan?

No

Who is EyePoint Pharmaceuticals' auditor?

Deloitte & Touche, LLP

Who is EyePoint Pharmaceuticals' legal counsel?

Ropes & Gray, LLP

EyePoint Pharmaceuticals